Results 171 to 180 of about 51,116 (225)

Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review. [PDF]

Ann Med
Li P, Li Y, Zhang L.
europepmc   +1 more source

Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. [PDF]

Eur Heart J Cardiovasc Pharmacother
Yang M, Henderson AD, Anand IS, Desai AS, Lam CSP, Maggioni AP, Martinez FA, Rouleau JL, Swedberg K, Vaduganathan M, van Veldhuisen DJ, Zannad F, Zile MR, Packer M, Rizkala A, Lewis EF, Jhund PS, Solomon SD, McMurray JJV.   +18 more
europepmc   +1 more source

A propensity score-matched retrospective study on sacubitril/valsartan use and 6-month readmission rates in patients with acute heart failure. [PDF]

PeerJ
Zhang L, Chen Q, Ren G.
europepmc   +1 more source

A sensitive green HPLC-fluorescence method for simultaneous analysis of sacubitril and valsartan in pure forms, pharmaceutical dosage form and human plasma. [PDF]

Sci Rep
Kormod LA, Hegazy MA, Kessiba AM.
europepmc   +1 more source

Early sacubitril/valsartan use associated with reduced atrial fibrillation risk in patients with acute myocardial infarction complicated by mitral regurgitation: a retrospective cohort study. [PDF]

Front Cardiovasc Med
Yin H, Zhou Y, Zhou Y, Ren L, Ma L.
europepmc   +1 more source

Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages.

JAMA Health Forum
Callaway Kim K, Roberts ET, Donohue JM, Sabik LM, Good CB, Devine JW, Tadrous M, Suda KJ.   +7 more
europepmc   +1 more source

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

New England Journal of Medicine, 2003
John J V Mcmurray, Eric J Velazquez, Aldo P Maggioni   +2 more
exaly   +2 more sources